Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Open Innovation for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Due Diligence
Comparison
 
Due Diligence
Overview
Top Applications
Online Panel Discussions
Request Consultation
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Articles

Pharmalicensing brings you advice, commentary and analysis from industry experts.

Articles Search

Search the Pharmalicensing articles directory by keyword. Alternatively our advanced search allows you to query by category, author and year of publishing.
 
Author Category
Year
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Recently Added

Ian Hardie, Business Development Manager from Scottish National Blood Transfusion Service spoke to Pharmalicensing about his experiences with the company and how it helped his NHS organisation sell 5 out of 8 patents with a sixth traded in another way. More
Based on over 500 hundred hours of research with the industry, the BioBusiness agenda has been carefully refined to ensure you meet and exceed your networking goals. More
The much-anticipated ICSE 2008 - the Pharmaceutical Contract Services Exhibition - is nearly upon us. This year the exhibition will be held at Messe Frankfurt, Germany from the 30th September until the 2nd October. For over 8 years, ICSE has been connecting buyers and sellers in the market of pharmaceutical contract services. It is the international platform for companies providing a diversity of outsourcing services including clinical trials, contract research, biotechnology and analytical services. More
Designed especially for branded and generic pharmaceutical companies, this conference drills into the complexities of Hatch-Waxman to reveal proven solutions, strategies, and tactics for mastering patent life cycle challenges. More
Early in June, Istanbul was the venue of one of the busiest EuroPLX Meetings ever. A last minute change to a more spacious conference room in the Istanbul Hilton Convention Center made sure that the 176 delegates of 123 companies from 31 countries had ample space to exchange their business opportunities. More

Most Viewed

Epilepsy, one of the oldest conditions known to mankind, is a neurological disorder characterised by recurrent, transient seizures caused by a disturbance in the electrical activity of the central nervous system. According to the World Health Organisation, up to 50 million people worldwide, equating to a prevalence of at least 50 per 100,000 of the general population will have epilepsy at any one time. More
In today's fervently age-conscious society, where maturity is widely regarded as a social handicap on a par with halitosis, why should women hoping to maintain their youthful good looks spend their days at sea level? And what could this possibly have to do with the adrenal gland? The answer is that women who live at high altitudes appear to age more quickly, because of lower levels of the adrenal hormones DHEA and DHEAS (dehydroepiandrosterone and dehydroepiandrosterone sulphate). However, a healthy adrenal gland does much more than act as endogenous botox... More
Bile has had a very bad press over the years. According to the humoral theory of medicine developed by the Ancient Greeks, the body consisted of four fluids (or humours), each of which gave off a specific vapour that ascended to the brain and defined the personality. More
The softgel delivery system offers improved, rapid and consistent absorption of hydrophobic drugs. More
If you had contracted tuberculosis (TB) in the first half of the last century, the most advanced treatment available was rest in a sanatorium and collapsing the lung; not surprisingly, the chances of survival were only around 50%. Cure rates soared in the developed world with the advent of antibiotics, but the latter years of the twentieth century saw a resurgence of the disease, with the emergence of multi-drug resistance and the deadly combination of tuberculosis and AIDS. Incidence rates have since generally declined, but the numbers involved are truly staggering. More
Partnering consultation free of charge
Biobusiness 2009
Bioiberica
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2009 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us